Phospholipase A2 and Phospholipase C (PLA2 and PLC)

Phospholipase A2 (PLA2) and Phospholipase C (PLC) are distinct families of enzymes that catalyze the hydrolysis of phospholipids, playing essential roles in cellular signaling and the inflammatory response (Source: UniProt). PLA2 enzymes release arachidonic acid from the cell membrane, which is then converted into pro-inflammatory eicosanoids such as prostaglandins and leukotrienes (Source: NIH). PLC enzymes hydrolyze phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG), which are critical for intracellular calcium signaling and protein kinase C activation (Source: PubMed). These enzymes are implicated in a wide range of pathologies, including atherosclerosis, rheumatoid arthritis, and various malignancies, making them attractive but complex therapeutic targets (Source: StatPearls). Drugs such as varespladib have been investigated for PLA2 inhibition, while compounds like edelfosine target PLC pathways, though clinical success has been limited by the high degree of isoform diversity and potential for off-target effects (Source: PubChem). Understanding the specific roles of different isoforms is crucial for developing effective therapies that can modulate these pathways without disrupting essential homeostatic functions (Source: PubMed).

Other names

Phosphatidylcholine 2-acylhydrolasePhosphoinositide phospholipase CLecithinase APhosphatidylinositol-specific phospholipase C

Inhibition of phospholipid hydrolysis to prevent the generation of lipid-derived second messengers and inflammatory precursors (Source: PubMed). PLA2 inhibitors block the release of arachidonic acid, while PLC inhibitors prevent the formation of IP3 and DAG (Source: NIH).